CLINICAL TRIALS PROFILE FOR ARISTADA INITIO KIT
✉ Email this page to a colleague
All Clinical Trials for ARISTADA INITIO KIT
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT03345979 ↗ | A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia | Completed | Alkermes, Inc. | Phase 3 | 2017-11-15 | This study will evaluate the efficacy of initiating treatment of schizophrenia with ARISTADA INITIO plus 30 mg oral aripiprazole followed by a 2-month dose of AL. |
NCT04203056 ↗ | Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode | Recruiting | Alkermes, Inc. | Phase 4 | 2019-12-16 | This 12-month study will evaluate the efficacy of aripiprazole lauroxil compared to oral aripiprazole in preventing the re-emergence of psychotic symptoms in patients with a recent onset of schizophrenia. |
NCT04203056 ↗ | Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode | Recruiting | University of California, Los Angeles | Phase 4 | 2019-12-16 | This 12-month study will evaluate the efficacy of aripiprazole lauroxil compared to oral aripiprazole in preventing the re-emergence of psychotic symptoms in patients with a recent onset of schizophrenia. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ARISTADA INITIO KIT
Condition Name
Clinical Trial Locations for ARISTADA INITIO KIT
Trials by Country
Clinical Trial Progress for ARISTADA INITIO KIT
Clinical Trial Phase
Clinical Trial Sponsors for ARISTADA INITIO KIT
Sponsor Name